JP2025506472A5 - - Google Patents

Info

Publication number
JP2025506472A5
JP2025506472A5 JP2024547294A JP2024547294A JP2025506472A5 JP 2025506472 A5 JP2025506472 A5 JP 2025506472A5 JP 2024547294 A JP2024547294 A JP 2024547294A JP 2024547294 A JP2024547294 A JP 2024547294A JP 2025506472 A5 JP2025506472 A5 JP 2025506472A5
Authority
JP
Japan
Prior art keywords
seq
composition according
vaccine composition
liposome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/053259 external-priority patent/WO2023152260A1/en
Publication of JP2025506472A publication Critical patent/JP2025506472A/ja
Publication of JP2025506472A5 publication Critical patent/JP2025506472A5/ja
Pending legal-status Critical Current

Links

JP2024547294A 2022-02-09 2023-02-09 抗アルファシヌクレイン治療的ワクチン Pending JP2025506472A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156006.3 2022-02-09
EP22156006 2022-02-09
EP22156007.1 2022-02-09
EP22156007 2022-02-09
PCT/EP2023/053259 WO2023152260A1 (en) 2022-02-09 2023-02-09 Anti-alpha-synuclein therapeutic vaccines

Publications (2)

Publication Number Publication Date
JP2025506472A JP2025506472A (ja) 2025-03-11
JP2025506472A5 true JP2025506472A5 (cg-RX-API-DMAC7.html) 2026-02-13

Family

ID=85175955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547294A Pending JP2025506472A (ja) 2022-02-09 2023-02-09 抗アルファシヌクレイン治療的ワクチン

Country Status (11)

Country Link
US (1) US20250152684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475878A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506472A (cg-RX-API-DMAC7.html)
KR (1) KR20240147981A (cg-RX-API-DMAC7.html)
AU (1) AU2023219059A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002370A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240371A (cg-RX-API-DMAC7.html)
IL (1) IL314865A (cg-RX-API-DMAC7.html)
MX (1) MX2024009485A (cg-RX-API-DMAC7.html)
WO (1) WO2023152260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250135293A (ko) * 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta
JP7898188B2 (ja) * 2020-08-04 2026-07-31 エイシー イミューン ソシエテ アノニム 免疫原性化合物

Similar Documents

Publication Publication Date Title
JP2021501147A5 (cg-RX-API-DMAC7.html)
JP2012522754A5 (cg-RX-API-DMAC7.html)
US20200140488A1 (en) Alzheimer's disease treatment method
JP2011529084A5 (cg-RX-API-DMAC7.html)
UA107571C2 (xx) Фармацевтична композиція
RU2011100125A (ru) Соединения для лечения амилоидозов
WO2005081872A3 (en) Methods and compositions comprising supramolecular constructs
JP2014531455A5 (cg-RX-API-DMAC7.html)
WO2006121656A3 (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JP2003503312A5 (cg-RX-API-DMAC7.html)
RU2011100126A (ru) Применение мимотопов для лечения бетта-амилоидозов
JP2025084745A5 (cg-RX-API-DMAC7.html)
US20230218730A1 (en) Vaccine therapy for ran protein diseases
JP2009541373A5 (cg-RX-API-DMAC7.html)
JPH10509428A (ja) 活性依存性神経栄養因子の神経栄養ペプチド
JP2021521149A5 (cg-RX-API-DMAC7.html)
JP2023541670A5 (cg-RX-API-DMAC7.html)
JP2023536497A5 (cg-RX-API-DMAC7.html)
JP2023541671A5 (cg-RX-API-DMAC7.html)
CN116261464A (zh) 免疫原性化合物
KR20240147981A (ko) 항-알파시누클레인 치료 백신
JP2022533422A5 (cg-RX-API-DMAC7.html)
EP1253938B1 (de) Immunisierung gegen Karzinome und ihre Vorstufen
US20220380425A1 (en) Angptl3 based vaccine for the treatment of liver disease
US20160303208A1 (en) Method for treating amyloid disease